TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06994676: A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Sponsor: Crossbow Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 72 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,382,304

Rescue Site Savings

+$911,064

Unlock Full NCT06994676 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06994676 Rescue Dossier →